DE60130865D1 - Benzimidazol-derivate als menschliche chymase - inhibitoren - Google Patents

Benzimidazol-derivate als menschliche chymase - inhibitoren

Info

Publication number
DE60130865D1
DE60130865D1 DE60130865T DE60130865T DE60130865D1 DE 60130865 D1 DE60130865 D1 DE 60130865D1 DE 60130865 T DE60130865 T DE 60130865T DE 60130865 T DE60130865 T DE 60130865T DE 60130865 D1 DE60130865 D1 DE 60130865D1
Authority
DE
Germany
Prior art keywords
halo
optionally substituted
oxo
trihalomethyl
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130865T
Other languages
English (en)
Other versions
DE60130865T2 (de
Inventor
Naoki Tsuchiya
Yoshiyuki Matsumoto
Hiroshi Saitou
Tsuyoshi Mizuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of DE60130865D1 publication Critical patent/DE60130865D1/de
Application granted granted Critical
Publication of DE60130865T2 publication Critical patent/DE60130865T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60130865T 2000-01-17 2001-01-17 Benzimidazol-derivate als menschliche chymase - inhibitoren Expired - Lifetime DE60130865T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000007533 2000-01-17
JP2000007533 2000-01-17
JP2000392303 2000-12-25
JP2000392303 2000-12-25
PCT/JP2001/000271 WO2001053291A1 (fr) 2000-01-17 2001-01-17 Derives benzimidazoles

Publications (2)

Publication Number Publication Date
DE60130865D1 true DE60130865D1 (de) 2007-11-22
DE60130865T2 DE60130865T2 (de) 2008-07-17

Family

ID=26583615

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130865T Expired - Lifetime DE60130865T2 (de) 2000-01-17 2001-01-17 Benzimidazol-derivate als menschliche chymase - inhibitoren

Country Status (19)

Country Link
EP (1) EP1249450B1 (de)
JP (1) JP4059671B2 (de)
KR (2) KR20070057276A (de)
CN (2) CN100415723C (de)
AT (1) ATE375156T1 (de)
AU (2) AU777813B2 (de)
CA (1) CA2396908A1 (de)
CZ (1) CZ301504B6 (de)
DE (1) DE60130865T2 (de)
DK (1) DK1249450T3 (de)
ES (1) ES2295128T3 (de)
HK (1) HK1050009A1 (de)
IL (1) IL150565A0 (de)
NO (1) NO324049B1 (de)
NZ (1) NZ520028A (de)
PT (1) PT1249450E (de)
RU (1) RU2263674C2 (de)
SI (1) SI1249450T1 (de)
WO (1) WO2001053291A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362854B1 (de) * 2001-02-22 2007-10-31 Teijin Pharma Limited Benzo[b[thiophenderivate und Verfahren zu deren Herstellung
US6774245B2 (en) * 2001-05-07 2004-08-10 Teijin Limited 3-Hydroxymethylbenzo[b]thiophene derivatives and process for their preparation
NZ528291A (en) * 2001-08-24 2007-03-30 Teijin Ltd Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
CL2004001034A1 (es) * 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
AU2004266536A1 (en) * 2003-08-22 2005-03-03 Teijin Pharma Limited Drug containing chymase inhibitor as the active ingredient
WO2006052026A1 (ja) * 2004-11-12 2006-05-18 Teijin Pharma Limited ベンズイミダゾール誘導体の酸性塩及びその結晶
EP1915988A4 (de) 2005-08-18 2012-07-25 Teijin Pharma Ltd Tablette mit mehreren arzneihaltigen segmenten
CN101291656B (zh) 2005-08-18 2012-11-07 帝人制药株式会社 具有准确的用量分割功能的制剂
EP1947097A1 (de) 2005-10-27 2008-07-23 Teijin Pharma Limited Benzo[b]thiophenderivat und verfahren zu dessen herstellung
BRPI0617924A2 (pt) 2005-10-27 2016-08-23 Teijin Pharma Ltd processo de produção, e, composto
PE20070698A1 (es) 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
WO2008147697A1 (en) * 2007-05-22 2008-12-04 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
EP2167464B1 (de) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclische verbindungen als positive modulatoren des metabotropen glutamatrezeptors 2 (mglu2-rezeptor)
WO2008153129A1 (ja) * 2007-06-14 2008-12-18 Teijin Pharma Limited 尿酸値低下剤
WO2009133964A1 (ja) * 2008-04-28 2009-11-05 国立大学法人九州大学 酸化ストレス抑制剤
CA2736522C (en) * 2008-09-09 2016-09-13 Boehringer Ingelheim International Gmbh Aza-benzimidazolone chymase inhibitors
CA2737694C (en) 2008-09-26 2013-07-02 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
WO2010051176A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2777746C (en) * 2009-11-18 2019-05-14 Astrazeneca Ab Benzoimidazole compounds and uses thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
PT2855456T (pt) * 2012-05-04 2017-07-10 Novartis Ag Moduladores da via do complemento e usos dos mesmos
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9527839B2 (en) 2012-08-22 2016-12-27 Merck Sharp & Dohme Corp. Benzimidazole tetrahydropyran derivatives
EP2887807B1 (de) 2012-08-22 2019-09-18 Merck Sharp & Dohme Corp. Benzimidazol-hexahydrofuro[3,2-b]furanderivate als amp-aktivierte proteinkinase-aktivatoren
WO2014031441A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
US9868733B2 (en) 2012-08-22 2018-01-16 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydrofuran derivatives
US9382243B2 (en) 2012-08-22 2016-07-05 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydropyran derivatives
WO2014031515A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2747973T3 (es) 2013-11-15 2020-03-12 Merck Sharp & Dohme Compuestos tricíclicos antidiabéticos
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
CN111004125B (zh) * 2019-12-24 2022-11-22 东华理工大学 一种缩醛或缩酮化合物的制备方法
CN116903541B (zh) * 2023-08-14 2023-12-08 中国环境科学研究院 用于酚类污染物检测的酰基咪唑类化合物、制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430950A1 (fr) * 1978-07-10 1980-02-08 Delalande Sa Nouveaux derives heterocycliques de la benzimidazole, leur procede de preparation et leur application en therapeutique
DE2928055A1 (de) * 1978-07-12 1980-01-31 Eastman Kodak Co Verfahren zur verbesserung der widerstandsfaehigkeit von polyesterformkoerpern gegenueber einem abbau durch u.v.- licht
JPS62212386A (ja) * 1986-03-14 1987-09-18 Suntory Ltd ２−ピリジルメチルベンズイミダゾ−ル誘導体
JPH01265089A (ja) * 1988-04-15 1989-10-23 Zeria Pharmaceut Co Ltd 新規１−（イミダゾール−４−イル）メチルベンズイミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
US5527597A (en) * 1995-03-01 1996-06-18 Southern Mills, Inc. Stretchable flame resistant fabric
WO1999026932A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
JP3923255B2 (ja) * 1998-07-15 2007-05-30 帝人株式会社 チオベンズイミダゾール誘導体
BR0011997A (pt) * 1999-06-28 2002-03-05 Janssen Pharmaceutica Nv Inibidores da replicação do vìrus sincicial respiratório
CZ2001153A3 (cs) * 1999-07-14 2001-06-13 Teijin Ltd Thiobenzimidazolové deriváty

Also Published As

Publication number Publication date
EP1249450A4 (de) 2003-04-09
NO324049B1 (no) 2007-08-06
EP1249450A1 (de) 2002-10-16
CA2396908A1 (en) 2001-07-26
ES2295128T3 (es) 2008-04-16
NO20023415D0 (no) 2002-07-16
EP1249450B1 (de) 2007-10-10
JP4059671B2 (ja) 2008-03-12
CZ301504B6 (cs) 2010-03-24
ATE375156T1 (de) 2007-10-15
WO2001053291A1 (fr) 2001-07-26
KR20020065929A (ko) 2002-08-14
RU2263674C2 (ru) 2005-11-10
AU2005200172A1 (en) 2005-02-10
AU2005200172B2 (en) 2007-08-23
AU777813B2 (en) 2004-11-04
AU2704901A (en) 2001-07-31
KR20070057276A (ko) 2007-06-04
IL150565A0 (en) 2003-02-12
CN1198819C (zh) 2005-04-27
CN1418211A (zh) 2003-05-14
SI1249450T1 (sl) 2008-04-30
KR100763779B1 (ko) 2007-10-05
NO20023415L (no) 2002-07-16
DE60130865T2 (de) 2008-07-17
HK1050009A1 (en) 2003-06-06
PT1249450E (pt) 2008-01-02
CN100415723C (zh) 2008-09-03
CN1680339A (zh) 2005-10-12
RU2002122105A (ru) 2004-01-10
DK1249450T3 (da) 2008-02-11
NZ520028A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
DE60130865D1 (de) Benzimidazol-derivate als menschliche chymase - inhibitoren
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
DE502004005959D1 (de) Pyrimidin-2-on-verbindungen und ihre verwendung als dopamin-d3-rezeptorliganden
ATE540938T1 (de) Neue benzoxazinonderivate als langwirksame betamimetika zur behandlung von atemwegserkrankungen
ZA200203315B (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines.
ECSP055644A (es) Derivados de la quinolil-propil-piperidina y su utilización
DE60233736D1 (de) Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
RU2003136097A (ru) Производные фенилпиридинкарбонилпиперазина
DE69132713D1 (de) Benzylidenthiazolidinderivate, ihre Herstellung und ihre Anwendung als Lipidperoxid-Inhibitoren
MXPA05010760A (es) Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
ATE510830T1 (de) Chromen-4-on-derivate als selbstbräunungssubstanz
CY1110465T1 (el) Υποκατεστημενα παραγωγα ιμιδαζολινης
ES2172436A1 (es) Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
DE69414396D1 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
BR0108251A (pt) Derivado de pirrolopiridazina ou um sal deste farmaceuticamente aceitável, composição farmacêutica, agente contendo um derivado de pirrolopiridazina ou um sal deste farmaceuticamente aceitável, e, uso de um derivado de pirrolopiridazina ou um sal deste farmaceuticamente aceitável
JPH083044A (ja) 骨粗鬆症の予防または治療剤
HUP0002715A2 (hu) Benzotiofénszármazékok alkalmazása trombocitaszám csökkentésére szolgáló gyógyszerkészítmények előállítására
AR035219A1 (es) Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto
ATE229520T1 (de) Benzothiophenderivate als antithrombotische mitteln und zwischenprodukte
HUP0204131A2 (hu) Szacharinszármazékok, mint orálisan aktív elasztáz inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60333095D1 (de) Imidazolverbindungen und ihre verwendung als alpha-2 adrenorezeptorliganden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition